425 related articles for article (PubMed ID: 22265683)
1. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
3. Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
Dig Liver Dis; 2013 Jan; 45(1):82-3. PubMed ID: 23058851
[No Abstract] [Full Text] [Related]
4. Comment on "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Angelico F; Del Ben M; Pignatelli P; Violi F
Dig Liver Dis; 2013 Jan; 45(1):81-2. PubMed ID: 22917635
[No Abstract] [Full Text] [Related]
5. Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Yamagishi S; Maeda S; Hyogo H
Dig Liver Dis; 2013 Jan; 45(1):83-4. PubMed ID: 23099228
[No Abstract] [Full Text] [Related]
6. Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Yamagishi S
Dig Liver Dis; 2013 Jan; 45(1):82. PubMed ID: 22909420
[No Abstract] [Full Text] [Related]
7. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Samy W; Hassanian MA
Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
[TBL] [Abstract][Full Text] [Related]
8. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Preston RA; Harvey P; Herfert O; Dykstra G; Jukema JW; Sun F; Gillen D
J Clin Pharmacol; 2007 Dec; 47(12):1555-69. PubMed ID: 18048574
[TBL] [Abstract][Full Text] [Related]
10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
[TBL] [Abstract][Full Text] [Related]
12. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
13. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
Abel T; Fehér J; Dinya E; Gamal Eldin M; Kovács A
Orv Hetil; 2009 May; 150(21):989-93. PubMed ID: 19443308
[TBL] [Abstract][Full Text] [Related]
15. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi M
Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
[TBL] [Abstract][Full Text] [Related]
16. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin.
Gonciarz M; Gonciarz Z; Bielanski W; Mularczyk A; Konturek PC; Brzozowski T; Konturek SJ
J Physiol Pharmacol; 2010 Dec; 61(6):705-10. PubMed ID: 21224501
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
Kosmidou MS; Hatzitolios AI; Adamidou A; Giannopoulos S; Raikos N; Parharidis G; Milionis HJ
Am J Hypertens; 2008 Mar; 21(3):303-9. PubMed ID: 18202666
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
[TBL] [Abstract][Full Text] [Related]
19. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Gumprecht J; Gosho M; Budinski D; Hounslow N
Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Goldberg AC; Bays HE; Ballantyne CM; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Am J Cardiol; 2009 Feb; 103(4):515-22. PubMed ID: 19195513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
